The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).
 
Salman Punekar
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Neogene Therapeutics (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)
 
Jeffrey Ward
Employment - Pfizer (I)
Consulting or Advisory Role - AstraZeneca; Guidepoint Inc; Jazz Pharmaceuticals; Novocure; Obsidian Therapeutics
Research Funding - A2 Biotherapeutics (Inst); Asher Biotherapeutics (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Genmab (Inst); Harpoon therapeutics (Inst); Instil Bio (Inst); Novocure (Inst); Pfizer (Inst); Roche/Genentech (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Novocure
 
Jong Chul Park
Honoraria - Coherus Biosciences; MitoImmune; Selecxine
Consulting or Advisory Role - Hanall Biopharma; Hanmi Pharma
Research Funding - A2 Bio (Inst); A2 Biotherapeutics (Inst); Alentis Therapeutics (Inst); ALX Oncology (Inst); Ankyra Therapeutics (Inst); CUE Biopharma (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst)
 
Sandip Patel
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Certis Oncology Solutions; Compugen; Illumina; Iovance Biotherapeutics (Inst); Lilly; Lilly; Merck; Nektar; Novartis; Pfizer; Roche/Genentech; Tempus
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics; Takeda (Inst); Takeda (Inst)
 
David Maloney
Stock and Other Ownership Interests - A2 Biotherapeutics
Honoraria - A2 Biotherapeutics; Bristol-Myers Squibb/Celgene; Genentech/Roche; Gilead Sciences; Kite, a Gilead company; Lyell Immunopharma; Novartis; Umoja Biopharma
Consulting or Advisory Role - A2 Biotherapeutics; Celgene/Bristol-Myers Squibb; Genentech; NAVAN Technologies
Research Funding - Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on 4 provisional patents.
 
Oliver Dorigo
Honoraria - Blueprint Medicines
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; IMV; Merck; PSI CRO Deutschland; R-Pharm
Speakers' Bureau - Immunogen
Research Funding - AstraZeneca (Inst); BioEclipse Therapeutics (Inst); EMD Serono (Inst); Genentech (Inst); IMV (Inst); Millennium (Inst); Novartis (Inst); PharmaMar (Inst)
 
Kedar Kirtane
Leadership - MyCareGorithm
Stock and Other Ownership Interests - Agenus; Oncternal Therapeutics; Veru
Consulting or Advisory Role - MyCareGorithm
Research Funding - Turnstone Bio
Travel, Accommodations, Expenses - A2Bio
 
Marcela Maus
Leadership - 2seventy bio
Stock and Other Ownership Interests - 2seventy bio; A2Bio; Affyimumune; BendBio; CARGO Therapeutics; GBM newco; Model T Bio; NexImmune; Oncternal Therapeutics
Consulting or Advisory Role - Adaptimmune; AffyImmune Therapeutics; Agenus; arcellx; Astellas Pharma; AstraZeneca; Atara Biotherapeutics; Bayer; BMS; Cabaletta Bio; Cabaletta Bio; Chugai Pharma; crispr therapeutics; GlaxoSmithKline; In8Bio; In8bio; Intellia Therapeutics; Kite, a Gilead company; MicroMedicine; Novartis; Oncternal Therapeutics; Sanofi; TCR2 Therapeutics; Tmunity Therapeutics, Inc.; Torque; windmil
Research Funding - Kite, a Gilead company (Inst); Moderna Therapeutics (Inst); Servier (Inst); Sobi (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patents held by Massachusetts General Hospital/Partners Health care; all related to CAR T cells and/or gene therapy; Inventor on patents held by U. Pennsylvania with and without Novartis
 
Maria Pia Morelli
No Relationships to Disclose
 
Yanyan Lou
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Turning Point Therapeutics
Research Funding - Blueprint Medicines (Inst); Daiichi-Sankyo (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Tolero Pharmaceuticals (Inst)
 
Matthew Block
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Marker, Inc. (Inst); Merck (Inst); nference (Inst); Perspective Therapeutics (Inst); Pharmacyclics (Inst); Regeneron (Inst); Sorrento Therapeutics (Inst); TILT Biotherapeutics (Inst); Transgene (Inst); Viewpoint Molecular Targeting (Inst)
Patents, Royalties, Other Intellectual Property - Combinations of Dendritic Cell-Based Vaccines and Checkpoint Inhibitors, patent pending (Inst); Dendritic Cell-Based Vaccines and Uses Thereof, patent pending (Inst)
(OPTIONAL) Uncompensated Relationships - Sorrento Therapeutics; TILT Biotherapeutics; Viewpoint Molecular Targeting
 
Monica Avila
No Relationships to Disclose
 
Ramez Eskander
No Relationships to Disclose
 
Leslie Boyd
Consulting or Advisory Role - AstraZeneca
 
Armen Mardiros
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
 
John Welch
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
Consulting or Advisory Role - Agios; Archer
Research Funding - Janssen (Inst); Notable Labs (Inst)
 
Andrea Wise
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
 
Jacqueline Xuan
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
 
Julian Molina
No Relationships to Disclose
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals; Trumvira
Consulting or Advisory Role - Agenus; Astellas Pharma; BeiGene; Bristol-Myers Squibb/Medarex; Galvanize Therapeutics; MBQ Pharma; Revolution Medicines; Taiho Pharmaceutical; Xilio Therapeutics
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)